What are the first‑line guideline‑directed medical therapies for chronic heart failure with reduced ejection fraction?

First-Line Guideline-Directed Medical Therapy for Heart Failure with Reduced Ejection Fraction

All patients with HFrEF should be initiated on four foundational medication classes: an angiotensin receptor-neprilysin inhibitor (ARNI) or ACE inhibitor, an evidence-based beta blocker, a mineralocorticoid receptor antagonist (MRA), and an SGLT2 inhibitor. 1

The Four Pillars of GDMT for HFrEF

1. Renin-Angiotensin System Inhibition (First Priority)

Start with ARNI (sacubitril/valsartan) as the preferred first-line agent for patients with NYHA class II-III symptoms, as it reduces both morbidity and mortality more effectively than ACE inhibitors alone. 1

• ARNI (sacubitril/valsartan): Class 1A recommendation for NYHA class II-III HFrEF 1
• ACE inhibitors: Use only when ARNI is not feasible (Class 1A recommendation) 1
• ARBs: Reserve for patients intolerant to ACE inhibitors due to cough or angioedema when ARNI is not feasible (Class 1A recommendation) 1
• If already on ACE inhibitor or ARB: Switch to ARNI to further reduce morbidity and mortality (Class 1B-R recommendation) 1

The evidence strongly favors ARNI over traditional ACE inhibitors, with sacubitril/valsartan demonstrating a 42% improvement in LVEF and significant reductions in left ventricular volumes after one year of therapy. 2

2. Evidence-Based Beta Blockers (Initiate Concurrently)

Use one of three proven beta blockers: bisoprolol, carvedilol, or sustained-release metoprolol succinate (Class 1A recommendation). 1

• These specific agents have mortality reduction data; other beta blockers do not carry the same evidence base 1
• Should be initiated in all patients with current or previous HFrEF symptoms 1
• Achieve 92% utilization rates in real-world practice when prioritized 3

3. Mineralocorticoid Receptor Antagonists (Essential Third Pillar)

Initiate spironolactone or eplerenone in NYHA class II-IV patients with eGFR >30 mL/min/1.73 m² and potassium <5.0 mEq/L (Class 1A recommendation). 1

• Requires careful monitoring of potassium and renal function at initiation and thereafter 1
• Real-world data shows 95% of hospitalized HFrEF patients can be discharged on MRA therapy when actively pursued 4
• The non-steroidal MRA finerenone represents an alternative with potentially lower hyperkalemia risk, though primarily studied in HFmrEF/HFpEF populations 5

4. SGLT2 Inhibitors (The Fourth Pillar)

Add an SGLT2 inhibitor (dapagliflozin or empagliflozin) to the regimen regardless of diabetes status, as this class now represents a cornerstone of HFrEF therapy. 1, 6

• SGLT2 inhibitors are now included as the fourth medication class in GDMT with strong evidence for mortality and morbidity reduction 1
• Can be initiated early, with 84% of HFrEF patients eligible for therapy 4
• Benefits extend beyond glycemic control to direct cardiovascular protection 6

Implementation Strategy

Initiate all four medication classes as rapidly as possible following HFrEF diagnosis, rather than sequential titration. 6, 7

• Current real-world data reveals significant gaps: only 18% receive triple therapy within 3 months of diagnosis, and SGLT2 inhibitor use remains at only 26-30% even after 12 months 3
• Hospitalization for heart failure represents a critical opportunity to optimize GDMT, with studies showing achievement of 77% triple therapy and 11% quadruple therapy rates at discharge when actively pursued 4
• The oldest patients (≥90 years) derive substantial benefit, with cardiovascular hospitalization rates dropping from 0.78 to 0.42 events/year with ARNI therapy 8

Critical Monitoring Parameters

Monitor potassium, renal function, and blood pressure closely after initiation, but do not allow fear of complications to prevent appropriate therapy. 9

• Symptomatic hypotension, hyperkalemia, and worsening renal function can be managed with dose adjustments and diuretic modification rather than discontinuation of life-saving medications 9
• Lower baseline LVEF predicts greater magnitude of reverse remodeling with GDMT 2

Common Pitfalls to Avoid

Do not delay SGLT2 inhibitor or ARNI initiation while waiting to "stabilize" patients on older therapies—this represents outdated practice. 6, 3

• The sequential approach of starting ACE inhibitors first, then switching to ARNI later, delays optimal therapy 3
• Only 19% of patients receive ARNI within the first year of diagnosis in real-world practice, despite 83% being eligible 4
• Underutilization stems from lack of awareness about safe initiation rather than true contraindications 7

Avoid using non-evidence-based beta blockers (such as atenolol or metoprolol tartrate)—only bisoprolol, carvedilol, and metoprolol succinate have mortality data. 1